SCHEMBL8790684

SCHEMBL8790684

NC(O)Cc1c(Cl)cccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.46
AKR1B1 P15121 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
ADRA2A P08913 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
OPRK1 P41145 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
HTR1A P08908 1/20 0.40
CYP2C9 P11712 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
MAOA P21397 1/20 0.40
ADRA1D P25100 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7651165 0.78 TAAR1 (0.43) TAAR1AKR1B1SMN1; SMN2ADRA2ACYP3A4
SCHEMBL7651167 0.78 TAAR1 (0.43) TAAR1AKR1B1SMN1; SMN2ADRA2ACYP3A4
SCHEMBL2426412 0.77 AKR1B1 (0.43) TAAR1AKR1B1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL11276473 0.77 SLC6A2 (0.54) TAAR1CYP3A4CYP2D6LMNAMAOA
SCHEMBL15083012 0.77 AKR1B1 (0.43) TAAR1AKR1B1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL13692457 0.77 SLC6A2 (0.54) TAAR1CYP3A4CYP2D6LMNAMAOA
SCHEMBL3058311 0.76 PNMT (0.52) TAAR1SMN1; SMN2CYP3A4CYP2D6LMNA
SCHEMBL10325433 0.76 AKR1B1 (0.42) TAAR1AKR1B1SMN1; SMN2ADRA2ACYP3A4
SCHEMBL16054505 0.76 AKR1B1 (0.42) TAAR1AKR1B1SMN1; SMN2ADRA2ACYP3A4
SCHEMBL2511832 0.76 TAAR1 (0.50) TAAR1AKR1B1SMN1; SMN2ADRA2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0620809-B1 $g(a)-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 1997-03-05 EP disclosed
US-5480912-A Method of treating HIV-1 with α-substituted benzenemethanamine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 1996-01-02 US disclosed
US-5407961-A Useful for treating HIV-1 virus JANSSEN PHARMACEUTICA N.V. (BE) 1995-04-18 US disclosed
EP-0620809-A1 -g(a)-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES. JANSSEN PHARMACEUTICA NV (BE) 1994-10-26 EP disclosed
WO-1993013052-A1 α-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1993-07-08 WO disclosed